Hespera Pharma

Unity Biotechnology (originally founded as Hespera Pharma) is a clinical-stage biopharmaceutical company focused on developing a new class of therapeutics to extend healthspan by targeting the biological mechanisms of aging. The company's primary approach involves "senolytic" medicines, which are small molecules designed to selectively eliminate senescent cells—cells that have stopped dividing but remain metabolically active and secrete pro-inflammatory factors that drive chronic disease. Unity's lead program, UBX1325 (foselutoclax), is a potent inhibitor of Bcl-xL currently being evaluated in Phase 2 clinical trials for ophthalmologic conditions such as diabetic macular edema and age-related macular degeneration. By clearing these "zombie cells," the company aims to restore tissue function and provide transformative treatments for a wide range of age-associated pathologies, including metabolic and neurological disorders.